H. Pylori: What 44% of the World Is Carrying, How Eradication Works, and the Role of Probiotics Before and After Triple Therapy
Updated: June 2026H pylori treatment · H pylori symptoms · H pylori eradication · H pylori triple therapy · H pylori probiotics · H pylori natural treatment · H pylori diet · H pylori test · helicobacter pylori treatment · H pylori antibiotic resistance · H pylori mastic gum · saccharomyces boulardii H pylori · lactobacillus reuteri H pylori · H pylori stomach ulcer · H pylori gastric cancer risk · H pylori breath test · H pylori stool antigen test · H pylori clarithromycin resistance · H pylori bismuth quadruple therapy · H pylori reinfection · how to treat H pylori naturally · H pylori after antibiotics · H pylori stomach pain · H pylori iron deficiency · H pylori causes · H pylori prevalence worldwide · WHO carcinogen H pylori
Helicobacter pylori is one of the most successful human pathogens in history: it has co-evolved with humans for at least 100,000 years, infects an estimated 44% of the global population (roughly 3.5 billion people), and establishes a persistent infection that, left untreated, lasts a lifetime. The WHO classified H. pylori as a Group 1 carcinogen (definite human carcinogen) in 1994 — it is the leading cause of peptic ulcer disease and is directly responsible for approximately 89% of non-cardia gastric cancers and 78% of duodenal ulcers.
Ready to fix this at the root?
The 30-Day Gut Reset is the full day-by-day protocol — mechanisms, dosed repair steps, a diagnostic chapter, food/swap tables, and a maintenance plan, built from the same research on this page.
Get the Gut Reset → $19
Most H. pylori infections are asymptomatic for decades. The bacteria survive the stomach's acid environment through an extraordinary adaptation: they produce urease, an enzyme that converts urea (abundant in gastric juice) to ammonia and CO2, creating a neutral microenvironment around the bacteria and neutralizing the acid that would destroy any other organism. Over years, this urease activity combined with H. pylori's direct inflammatory effects on the gastric epithelium produces chronic gastritis, which in a subset of patients progresses to ulcers, atrophic gastritis, intestinal metaplasia, and ultimately gastric cancer — a decades-long progression that is entirely preventable with eradication.
44%
global H. pylori prevalence — Hooi 2017 (Gastroenterology, systematic review of 189 studies): 44.3% global prevalence; marked geographic variation: developing countries 70–80% (Sub-Saharan Africa, South/Southeast Asia); Western Europe 25–35%; USA 30–40% (higher in immigrants and lower socioeconomic groups); transmission: oral-oral (saliva, dental plaques), fecal-oral (contaminated water); primarily acquired in childhood (living in crowded conditions, shared beds, unsafe water); spontaneous clearance is extremely rare without treatment — infection is effectively permanent without eradication therapy; H. pylori positive status + first-degree relative with gastric cancer → particularly strong indication to eradicate
Urease
the survival mechanism — H. pylori survives gastric acid (pH 1.5–3.5) via urease enzyme: converts urea → ammonia (NH3) + CO2; ammonia neutralizes acid immediately around the bacteria (creates microenvironment pH ~6–7); urease also damages the gastric mucus layer directly; this is the basis of the urea breath test (UBT): patient ingests 13C-labeled urea → if H. pylori present → 13CO2 detected in exhaled breath; UBT is 96% sensitive, 93% specific — the most accurate non-invasive test; stool antigen test (HpSA monoclonal) is comparable (~94% sensitivity, 97% specificity) and cheaper; serology (IgG antibodies) detects past OR present infection only — not useful for confirming eradication
Triple
standard eradication: triple therapy 14 days — PPI (omeprazole 20mg or equivalent) twice daily + clarithromycin 500mg twice daily + amoxicillin 1g twice daily; 14 days (vs 7 days) significantly improves eradication rates: Fischbach 2007 meta-analysis: 14-day triple therapy ~85% eradication vs ~75% for 7-day; eradication must be confirmed: UBT or stool antigen 4–6 weeks after completing antibiotics (not sooner — false negatives from residual antibiotic effect); PPI must be stopped 2 weeks before test; IMPORTANT: clarithromycin resistance is increasing (>20% in many regions — US, Europe) significantly reducing triple therapy effectiveness → bismuth quadruple therapy now preferred first-line in high-resistance areas
+12%
probiotic adjunct effect on eradication rate — Dang 2014 (PLOS ONE, meta-analysis of 45 RCTs, N=5,792): adding probiotics to H. pylori eradication therapy → eradication rate improvement of approximately 12 percentage points (from ~75% to ~87%); strongest evidence: Saccharomyces boulardii (reduces clarithromycin degradation, creates hostile environment for H. pylori, reduces C. diff risk) and Lactobacillus reuteri (directly inhibits H. pylori adhesion via competitive exclusion, ATCC 55730 and DSM 17938 strains); additional probiotic benefit: significant reduction in antibiotic-associated side effects — diarrhea -60%, nausea -35%, bloating -40%; timing: take probiotics 2 hours away from antibiotics